AI-generated summary
The authors randomized 60 Indian patients with recalcitrant melasma into three groups of 20 to receive one of three laser treatments over five sessions. All groups showed a significant reduction in mMASI scores, with the erbium YAG laser giving the largest reduction and homogeneity gains, and the authors report that all three modalities were effective and safe. The abstract notes the study's relatively small groups and that the findings come from a single comparative trial.
- Participants
- 60
- Who or what was studied
- Sixty Indian patients with recalcitrant melasma, randomized into three groups of 20
- Wavelengths
- 540, 1064, 2940 nm
- Limits stated in the abstract
- The abstract reports small group sizes of 20 patients each and evaluation by blinded comparison of photographs, with follow-up of only 6 months.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 1064 nm, 540 nm, 2940 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.